An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy

This publication has 17 references indexed in Scilit:

• Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
  New England Journal of Medicine, 2006
• BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
  Blood, 2006
• The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
  Leukemia, 2006
• Splicing in action: assessing disease causing sequence changes
  Journal of Medical Genetics, 2005
• The development of imatinib as a therapeutic agent for chronic myeloid leukemia
  Blood, 2005
• Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
  Blood, 2004
• Regulation of the c-Abl and Bcr–Abl tyrosine kinases
  Nature Reviews Molecular Cell Biology, 2004
• Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
  New England Journal of Medicine, 2003
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
  Cancer Cell, 2002
• High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
  Blood, 2002